JNJ-54175446

Legal status

• Investigational New Drug

CAS Number

• 1627902-21-9 ^Y

PubChem CID

• 90409366

DrugBank

• DB15358

JNJ-54175446

Legal status
Legal status	Investigational New Drug
Identifiers
IUPAC name (R)-(2-chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyrimidin-2-yl)-4-methyl-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)methanone
CAS Number	1627902-21-9 Y
PubChem CID	90409366
DrugBank	DB15358
ChemSpider	58828285
UNII	32524GLF40
ChEMBL	ChEMBL4079239
Chemical and physical data
Formula	C18H13ClF4N6O
Molar mass	440.79 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H]1C2=C(CCN1C(=O)C3=C(C(=CC=C3)C(F)(F)F)Cl)N(N=N2)C4=NC=C(C=N4)F
InChI InChI=1S/C18H13ClF4N6O/c1-9-15-13(29(27-26-15)17-24-7-10(20)8-25-17)5-6-28(9)16(30)11-3-2-4-12(14(11)19)18(21,22)23/h2-4,7-9H,5-6H2,1H3/t9-/m1/s1 Key:CWFVVQFVGMFTBD-SECBINFHSA-N

JNJ-54175446 is an investigational P2X7 receptor antagonist developed by Janssen Pharmaceuticals. It is hoped that the drug can reduce neuroinflammation and therefore treat psychiatric disorders such as major depressive disorder.^{[1][2][3][4][5][6]}